Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
API SUPPLIERS
NDC Package Code : 12714-234
Start Marketing Date : 2000-06-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER, FOR SOLUTION (50mg/50mg)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 12714-236
Start Marketing Date : 2000-06-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER, FOR SOLUTION (25mg/25mg)
Marketing Category : DRUG FOR FURTHER PROCESSING
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
TNKase (tenecteplase) is a tissue plasminogen activator, indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).
Lead Product(s): Tenecteplase
Therapeutic Area: Neurology Brand Name: TNKase
Study Phase: Approved FDFProduct Type: Enzyme
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 03, 2025
Lead Product(s) : Tenecteplase
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
Details : TNKase (tenecteplase) is a tissue plasminogen activator, indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).
Product Name : TNKase
Product Type : Enzyme
Upfront Cash : Inapplicable
March 03, 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info :
Registration Country : Sweden
Brand Name : Metalyse
Dosage Form : PULVER OCH VÄTSKA TILL INJEKTIONSVÄTSKA
Dosage Strength : 8000 ENHETER
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Metalyse
Dosage Form : PULVER OCH VÄTSKA TILL INJEKTIONSVÄTSKA
Dosage Strength : 10 000 ENHETER
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Metalyse
Dosage Form : Powder for solution for injection
Dosage Strength : 5,000 E
Packaging : Vials 5000E
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
Market Place
ABOUT THIS PAGE
